ProCognia (Israel) Ltd. (TASE:PRCG) today announced that it has obtained approval from the Sheba Medical Center Tel Hashomer's ethics (Helsinki) committee to conduct a human diagnostic trial of its glucose biomarker to diagnose colon cancer and inflammations.
The trial will be conducted at Sheba Medical Center. ProCognia aims to develop a diagnostic kit for colon cancer through a blood test and on the basis of it proprietary technology. The trial will monitor the differences between patients with varying stages of colon cancer and healthy people by comparing their blood sugar levels, known as glycoanalysis.
The trial follows the preliminary results, obtained in September 2009, which found significant differences in blood sugar levels between patients with stomach and pancreas cancer and healthy people.
ProCognia's share rose 0.1% by midday today to NIS 0.77, giving a market cap of NIS 17 million.
Published by Globes [online], Israel business news - www.globes-online.com - on January 20, 2010
© Copyright of Globes Publisher Itonut (1983) Ltd. 2010